<DOC>
	<DOCNO>NCT00560300</DOCNO>
	<brief_summary>To examine effect two type active vitamin D ( calcitriol doxercalciferol ) two phosphate binder ( sevelamer calcium carbonate ) bone disease blood test child kidney failure</brief_summary>
	<brief_title>Regulation Bone Formation Renal Osteodystrophy</brief_title>
	<detailed_description>Pediatric patient treat CCPD display biochemical bone biopsy proven secondary hyperparathyroidism randomly assign one 2 vitamin D analogue ( calcitriol doxercalciferol ) one two phosphate binder ( sevelamer calcium carbonate ) two two factorial design prospective trial . Serum biochemical measurement obtain baseline monthly throughout 8 month trial . Bone biopsy obtaine baseline repeat study completion .</detailed_description>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Renal Osteodystrophy</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>1 alpha-hydroxyergocalciferol</mesh_term>
	<mesh_term>Dihydroxycholecalciferols</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>Stable endstage kidney disease treat continuous cycling peritoneal dialysis , Biochemical evidence secondary hyperparathyroidism ( PTH &gt; 400 pg/ml ) bone biopsy evidence high turnover bone disease History parathyroidectomy Growth hormone Prednisone , immunosuppressant medication within past year . Recent history medication noncompliance .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>